Results 211 to 220 of about 172,520 (296)

Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases

open access: yesObesity Reviews, EarlyView.
ABSTRACT Epidemiological evidence shows that obesity increases the risk of developing metabolic diseases. Nevertheless, the mechanisms behind this connection remain underappreciated. The substantial impact of these disorders on global health has led to extensive research efforts aimed at identifying the pathophysiological links between them.
Ghadeer Alhamar   +4 more
wiley   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

open access: yesObesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira   +8 more
wiley   +1 more source

Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes. [PDF]

open access: yesJACC Basic Transl Sci
Brown OI   +23 more
europepmc   +1 more source

Beyond Deterministic Fetal Programming: Intrauterine Exposures and the Multifactorial Origins of Adiposity

open access: yesObesity Reviews, EarlyView.
ABSTRACT Excess adiposity is not a recently developed problem but has existed since at least the upper Paleolithic, allowing evolutionary selection pressures to adapt the physiology of the pregnant woman and the feto‐placental unit for maternal and fetal protection.
Gernot Desoye   +6 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

open access: yesObesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani   +8 more
wiley   +1 more source

Editorial: Targeting adipose tissue for the treatment of metabolic alterations. [PDF]

open access: yesFront Pharmacol
Flori L   +3 more
europepmc   +1 more source

Novel Combination of UVA‐1 Phototherapy With Topical Tofacitinib for Treating Eosinophilic Fasciitis With Morphea: Case Report

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic ...
Daphne M. Cheung   +5 more
wiley   +1 more source

Caspase-6 Controls Lipid and Energy Metabolism in Diet-Induced Obesity. [PDF]

open access: yesAdv Sci (Weinh)
Gupta A   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy